Delta-Fly Pharma Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Kiyoshi Eshima

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	6.9yrs

Actualizaciones recientes de la dirección

Recent updates

We're A Little Worried About Delta-Fly Pharma's (TSE:4598) Cash Burn Rate

Sep 06

Is Delta-Fly Pharma (TSE:4598) In A Good Position To Deliver On Growth Plans?

May 22

CEO

Kiyoshi Eshima

no data

Permanencia

Mr. Kiyoshi Eshima serves as President & Representative Director of Delta-Fly Pharma, Inc.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Kiyoshi Eshima	President & Representative Director	no data	sin datos	sin datos
Kinichiro Kominami	Independent Outside Director	6.4yrs	sin datos	sin datos
Kenzo Iizuka	Director	11.8yrs	sin datos	1.03% ¥ 48.3m
Sachio Kishii	Independent Outside Director	7.4yrs	sin datos	sin datos
Masaya Kimura	Auditor	10.4yrs	sin datos	0.18% ¥ 8.5m
Shohei Yamamoto	External Auditor	9.8yrs	sin datos	sin datos
Kenichi Kurotaki	Director	4.4yrs	sin datos	sin datos
Akifumi Taniguchi	Independent Outside Director	3.4yrs	sin datos	sin datos
Masaaki Maeda	Full-Time Auditor	4.4yrs	sin datos	sin datos

6.9yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de 4598 se considera experimentada (6.9 años de antigüedad promedio).

Delta-Fly Pharma Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Delta-Fly Pharma, Inc., Annual General Meeting, Jun 27, 2024

Less than half of directors are independent

Delta-Fly Pharma, Inc., Annual General Meeting, Jun 29, 2022

Less than half of directors are independent

Recent updates

Delta-Fly Pharma Inc Provides Update for Expanded Phase I Study of DFP-14927

Delta-Fly Pharma Inc. announces Phase I/II Study of Dfp-10917 and Venetoclax in Aml Patients Begins with Promising Initial Data

We're A Little Worried About Delta-Fly Pharma's (TSE:4598) Cash Burn Rate

Delta-Fly Pharma, Inc. to Report Q2, 2025 Results on Nov 14, 2024

New major risk - Financial position

Delta-Fly Pharma, Inc. Announces Enrollment of Patients in the Phase III Clinical Trial of DFP-14323

Insufficient new directors

Delta-Fly Pharma, Inc. to Report Q1, 2025 Results on Aug 09, 2024

Is Delta-Fly Pharma (TSE:4598) In A Good Position To Deliver On Growth Plans?

Delta-Fly Pharma, Inc., Annual General Meeting, Jun 27, 2024

Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax

Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax (VTX) in the AML Patients Treated by VTX in the AML

Delta-Fly Pharma, Inc. to Report Fiscal Year 2024 Results on May 15, 2024

Delta-Fly Pharma Inc Announces Initiation of Phase III Pivotal Comparative Clinical Trial of DFP-14323

Delta-Fly Pharma Inc Announces Initiation of Phase III Pivotal Comparative Clinical Trial of DFP-14323

Delta-Fly Pharma, Inc. Provides Update on Interim Analysis Status of Phase III Study of DFP-10917 in Patients with R/R AML

Delta-Fly Pharma, Inc. to Report Q3, 2024 Results on Feb 13, 2024

New major risk - Shareholder dilution

New major risk - Share price stability

Delta-Fly Pharma, Inc. to Report Q2, 2024 Results on Nov 13, 2023

Delta-Fly Pharma, Inc. to Report Q1, 2024 Results on Aug 14, 2023

Third quarter 2023 earnings released: JP¥75.09 loss per share (vs JP¥51.67 loss in 3Q 2022)

Delta-Fly Pharma, Inc. announced that it has received ¥1.300842 billion in funding from Macquarie Group Limited

Delta-Fly Pharma, Inc. announced that it expects to receive ¥1.300842 billion in funding from Macquarie Group Limited

First half 2023 earnings released: JP¥115 loss per share (vs JP¥103 loss in 1H 2022)

Less than half of directors are independent

First quarter 2023 earnings released: JP¥56.83 loss per share (vs JP¥56.58 loss in 1Q 2022)

Delta-Fly Pharma, Inc. to Report Q3, 2023 Results on Feb 14, 2023

Delta-Fly Pharma, Inc., Annual General Meeting, Jun 29, 2022

Less than half of directors are independent

Delta-Fly Pharma, Inc. to Report Fiscal Year 2022 Results on May 13, 2022

New 90-day low: JP¥1,067

New 90-day low: JP¥1,119

New 90-day low: JP¥1,521

CEO

Permanencia

Miembros de la Junta

Permanencia media

Promedio de edad